![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BMPR2 |
Gene summary for BMPR2 |
![]() |
Gene information | Species | Human | Gene symbol | BMPR2 | Gene ID | 659 |
Gene name | bone morphogenetic protein receptor type 2 | |
Gene Alias | BMPR-II | |
Cytomap | 2q33.1-q33.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q13873 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
659 | BMPR2 | CA_HPV_1 | Human | Cervix | CC | 6.32e-03 | -9.49e-02 | 0.0264 |
659 | BMPR2 | CCI_2 | Human | Cervix | CC | 4.14e-16 | 2.38e+00 | 0.5249 |
659 | BMPR2 | CCI_3 | Human | Cervix | CC | 3.67e-18 | 1.16e+00 | 0.516 |
659 | BMPR2 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.55e-08 | 4.68e-01 | -0.1954 |
659 | BMPR2 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.07e-03 | 7.34e-01 | -0.2602 |
659 | BMPR2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 3.08e-13 | -4.45e-01 | 0.294 |
659 | BMPR2 | A001-C-207 | Human | Colorectum | FAP | 8.95e-03 | -2.21e-01 | 0.1278 |
659 | BMPR2 | A015-C-203 | Human | Colorectum | FAP | 7.53e-28 | -3.18e-01 | -0.1294 |
659 | BMPR2 | A015-C-204 | Human | Colorectum | FAP | 5.41e-05 | -1.89e-01 | -0.0228 |
659 | BMPR2 | A014-C-040 | Human | Colorectum | FAP | 4.43e-07 | -6.78e-01 | -0.1184 |
659 | BMPR2 | A002-C-201 | Human | Colorectum | FAP | 3.96e-14 | -3.40e-01 | 0.0324 |
659 | BMPR2 | A001-C-119 | Human | Colorectum | FAP | 1.22e-05 | 9.59e-03 | -0.1557 |
659 | BMPR2 | A001-C-108 | Human | Colorectum | FAP | 1.62e-16 | -1.65e-01 | -0.0272 |
659 | BMPR2 | A002-C-205 | Human | Colorectum | FAP | 2.27e-23 | -3.29e-01 | -0.1236 |
659 | BMPR2 | A015-C-005 | Human | Colorectum | FAP | 8.29e-06 | -4.12e-01 | -0.0336 |
659 | BMPR2 | A015-C-006 | Human | Colorectum | FAP | 3.59e-16 | -3.71e-01 | -0.0994 |
659 | BMPR2 | A015-C-106 | Human | Colorectum | FAP | 1.46e-10 | -2.28e-01 | -0.0511 |
659 | BMPR2 | A002-C-114 | Human | Colorectum | FAP | 1.91e-19 | -3.39e-01 | -0.1561 |
659 | BMPR2 | A015-C-104 | Human | Colorectum | FAP | 5.89e-32 | -4.30e-01 | -0.1899 |
659 | BMPR2 | A001-C-014 | Human | Colorectum | FAP | 6.04e-15 | -2.88e-01 | 0.0135 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:007149610 | Cervix | CC | cellular response to external stimulus | 78/2311 | 320/18723 | 1.82e-09 | 1.98e-07 | 78 |
GO:00506737 | Cervix | CC | epithelial cell proliferation | 98/2311 | 437/18723 | 2.01e-09 | 2.15e-07 | 98 |
GO:001063210 | Cervix | CC | regulation of epithelial cell migration | 72/2311 | 292/18723 | 4.52e-09 | 4.43e-07 | 72 |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00458608 | Cervix | CC | positive regulation of protein kinase activity | 85/2311 | 386/18723 | 5.61e-08 | 3.29e-06 | 85 |
GO:00506787 | Cervix | CC | regulation of epithelial cell proliferation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
GO:00106349 | Cervix | CC | positive regulation of epithelial cell migration | 47/2311 | 176/18723 | 1.73e-07 | 8.01e-06 | 47 |
GO:00316689 | Cervix | CC | cellular response to extracellular stimulus | 59/2311 | 246/18723 | 3.03e-07 | 1.24e-05 | 59 |
GO:00018908 | Cervix | CC | placenta development | 40/2311 | 144/18723 | 4.59e-07 | 1.77e-05 | 40 |
GO:00614588 | Cervix | CC | reproductive system development | 87/2311 | 427/18723 | 1.37e-06 | 4.55e-05 | 87 |
GO:00486088 | Cervix | CC | reproductive structure development | 86/2311 | 424/18723 | 1.90e-06 | 5.97e-05 | 86 |
GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
GO:00109757 | Cervix | CC | regulation of neuron projection development | 88/2311 | 445/18723 | 4.26e-06 | 1.09e-04 | 88 |
GO:00107206 | Cervix | CC | positive regulation of cell development | 64/2311 | 298/18723 | 5.69e-06 | 1.41e-04 | 64 |
GO:003166710 | Cervix | CC | response to nutrient levels | 92/2311 | 474/18723 | 5.80e-06 | 1.42e-04 | 92 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0541820 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa043908 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa05418110 | Cervix | CC | Fluid shear stress and atherosclerosis | 50/1267 | 139/8465 | 5.71e-10 | 1.32e-08 | 7.81e-09 | 50 |
hsa0436012 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa0439013 | Cervix | CC | Hippo signaling pathway | 40/1267 | 157/8465 | 3.64e-04 | 1.82e-03 | 1.07e-03 | 40 |
hsa05418 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
hsa04360 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa054181 | Colorectum | AD | Fluid shear stress and atherosclerosis | 54/2092 | 139/8465 | 1.41e-04 | 1.16e-03 | 7.37e-04 | 54 |
hsa043601 | Colorectum | AD | Axon guidance | 61/2092 | 182/8465 | 4.36e-03 | 2.17e-02 | 1.38e-02 | 61 |
hsa054182 | Colorectum | SER | Fluid shear stress and atherosclerosis | 40/1580 | 139/8465 | 2.28e-03 | 1.75e-02 | 1.27e-02 | 40 |
hsa04350 | Colorectum | SER | TGF-beta signaling pathway | 31/1580 | 108/8465 | 7.00e-03 | 3.77e-02 | 2.74e-02 | 31 |
hsa054183 | Colorectum | SER | Fluid shear stress and atherosclerosis | 40/1580 | 139/8465 | 2.28e-03 | 1.75e-02 | 1.27e-02 | 40 |
hsa043501 | Colorectum | SER | TGF-beta signaling pathway | 31/1580 | 108/8465 | 7.00e-03 | 3.77e-02 | 2.74e-02 | 31 |
hsa054184 | Colorectum | MSS | Fluid shear stress and atherosclerosis | 51/1875 | 139/8465 | 6.06e-05 | 5.80e-04 | 3.55e-04 | 51 |
hsa04390 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
hsa043602 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
hsa054185 | Colorectum | MSS | Fluid shear stress and atherosclerosis | 51/1875 | 139/8465 | 6.06e-05 | 5.80e-04 | 3.55e-04 | 51 |
hsa043901 | Colorectum | MSS | Hippo signaling pathway | 48/1875 | 157/8465 | 8.32e-03 | 3.10e-02 | 1.90e-02 | 48 |
hsa043603 | Colorectum | MSS | Axon guidance | 54/1875 | 182/8465 | 1.03e-02 | 3.69e-02 | 2.26e-02 | 54 |
Page: 1 2 3 4 5 6 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
BMP7 | ACVR1_BMPR2 | BMP7_ACVR1_BMPR2 | BMP | Cervix | CC |
BMP7 | BMPR1A_BMPR2 | BMP7_BMPR1A_BMPR2 | BMP | Cervix | CC |
BMP7 | BMPR1B_BMPR2 | BMP7_BMPR1B_BMPR2 | BMP | Cervix | CC |
BMP2 | BMPR1A_BMPR2 | BMP2_BMPR1A_BMPR2 | BMP | CRC | AD |
BMP4 | BMPR1A_BMPR2 | BMP4_BMPR1A_BMPR2 | BMP | CRC | AD |
BMP5 | BMPR1A_BMPR2 | BMP5_BMPR1A_BMPR2 | BMP | CRC | AD |
BMP6 | BMPR1A_BMPR2 | BMP6_BMPR1A_BMPR2 | BMP | CRC | AD |
BMP2 | BMPR1A_BMPR2 | BMP2_BMPR1A_BMPR2 | BMP | CRC | ADJ |
BMP4 | BMPR1A_BMPR2 | BMP4_BMPR1A_BMPR2 | BMP | CRC | ADJ |
BMP5 | BMPR1A_BMPR2 | BMP5_BMPR1A_BMPR2 | BMP | CRC | ADJ |
BMP6 | BMPR1A_BMPR2 | BMP6_BMPR1A_BMPR2 | BMP | CRC | ADJ |
BMP5 | BMPR1A_BMPR2 | BMP5_BMPR1A_BMPR2 | BMP | CRC | CRC |
BMP2 | BMPR1A_BMPR2 | BMP2_BMPR1A_BMPR2 | BMP | CRC | FAP |
BMP5 | BMPR1A_BMPR2 | BMP5_BMPR1A_BMPR2 | BMP | CRC | FAP |
BMP6 | BMPR1A_BMPR2 | BMP6_BMPR1A_BMPR2 | BMP | CRC | FAP |
BMP2 | BMPR1A_BMPR2 | BMP2_BMPR1A_BMPR2 | BMP | CRC | Healthy |
BMP4 | BMPR1A_BMPR2 | BMP4_BMPR1A_BMPR2 | BMP | CRC | MSI-H |
BMP6 | ACVR1_BMPR2 | BMP6_ACVR1_BMPR2 | BMP | CRC | MSI-H |
BMP6 | BMPR1A_BMPR2 | BMP6_BMPR1A_BMPR2 | BMP | CRC | MSI-H |
BMP4 | BMPR1A_BMPR2 | BMP4_BMPR1A_BMPR2 | BMP | CRC | SER |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BMPR2 | deletion | Frame_Shift_Del | rs772920507 | c.1742delN | p.Asn583ThrfsTer44 | p.N583Tfs*44 | Q13873 | protein_coding | TCGA-BR-8382-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
BMPR2 | deletion | Frame_Shift_Del | rs772920507 | c.1748delA | p.Asn583ThrfsTer44 | p.N583Tfs*44 | Q13873 | protein_coding | TCGA-BR-8487-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
BMPR2 | deletion | Frame_Shift_Del | rs772920507 | c.1748delA | p.Asn583ThrfsTer44 | p.N583Tfs*44 | Q13873 | protein_coding | TCGA-BR-8591-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
BMPR2 | deletion | Frame_Shift_Del | novel | c.1028delA | p.Asn343MetfsTer14 | p.N343Mfs*14 | Q13873 | protein_coding | TCGA-CD-A4MJ-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR | ||
BMPR2 | deletion | Frame_Shift_Del | rs772920507 | c.1748delA | p.Asn583ThrfsTer44 | p.N583Tfs*44 | Q13873 | protein_coding | TCGA-CD-A4MJ-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR | ||
BMPR2 | deletion | Frame_Shift_Del | novel | c.393delT | p.Pro132HisfsTer20 | p.P132Hfs*20 | Q13873 | protein_coding | TCGA-F1-6874-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | ||
BMPR2 | deletion | Frame_Shift_Del | rs772920507 | c.1748delA | p.Asn583ThrfsTer44 | p.N583Tfs*44 | Q13873 | protein_coding | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD | ||
BMPR2 | deletion | Frame_Shift_Del | rs772920507 | c.1742delN | p.Asn583ThrfsTer44 | p.N583Tfs*44 | Q13873 | protein_coding | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | ||
BMPR2 | deletion | Frame_Shift_Del | rs772920507 | c.1742delN | p.Asn583ThrfsTer44 | p.N583Tfs*44 | Q13873 | protein_coding | TCGA-HU-A4GN-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | mitomycin | PD | ||
BMPR2 | deletion | Frame_Shift_Del | rs772920507 | c.1748delA | p.Asn583ThrfsTer44 | p.N583Tfs*44 | Q13873 | protein_coding | TCGA-HU-A4GT-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | copolang | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
659 | BMPR2 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, CELL SURFACE | inhibitor | 249565835 | ||
659 | BMPR2 | KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, CELL SURFACE | inhibitor | 385612192 |
Page: 1 |